Ipsen – Option agreement to acquire Canbex Therapeutics – Businesswire

Ipsen will complement its portfolio with the acquisition of the UK biotech, Canbex Therapeutics

MS_and_the_Brain_DamageCanbex has granted Ipsen an option giving Ipsen the exclusive right to purchase 100% of Canbex shares upon completion of the Phase IIa study of Canbex’s lead candidate for the treatment of spasticity in people with multiple sclerosis (MS), known as VSN16R (Phase I successfully completed). As stated by Marc de Garidel, Chairman and CEO of Ipsen, “it could be a valuable companion product to Dysport® in the treatment of spasticity”. Read more

New York biotech hub is struggling – Fast Company

The Big Apple’s biotech dreams are stuck in the Petri dish

NYCThe nation’s bigger biotech hubs, like those in Boston and the Bay Area, beckon promising biotech startups with their well-bred gene pools of talent, real estate, and investors. Even as the biotech industry as a whole reaches new highs, this is an ecosystem that New York City—home base to so many other industries—has struggled to build. There’s a deep incongruity here. The city boasts nine of the country’s top medical centers, and the state ranks in the top three for National Institutes of Health awards. Read more

AstraZeneca Launches USD 40m Early-Stage Anti-Infectives R&D Unit – GEN News

AstraZeneca will spin-off its anti-infectives R&D unit

test-214185_1280AstraZeneca will spend USD 40 million to create a new stand-alone subsidiary focused on early-stage research and development of small molecule anti-infectives. AstraZeneca is one of the big Pharma, together with Roche, that is focusing on the development of new solutions for drug-resistant bacteria. Read more

How to Develop New Antibiotics – New York Times

Why is it key to rethink antibiotics development?

EHEC Outbreak Claims 11 LivesHere’s a very compelling article written by about it.

THE bacteria are winning. Every year, according to the Centers for Disease Control and Prevention, at least two million people are infected with bacteria that can’t be wiped out with antibiotics, and as a result, 23,000 people die. Direct health care costs from these illnesses are estimated to be as high as $20 billion annually. Read more